AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference

LEXINGTON, Mass.–(BUSINESS WIRE)–Feb. 7, 2013–
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William
Heiden, AMAG’s chief executive officer, will participate in the Leerink
Swann Global Healthcare Conference on Wednesday, February 13, 2013 at
2:00 pm Eastern Time. The presentation will include a company overview
and business update, followed by a question and answer session with
investors.

A live webcast of the presentation will be accessible through the
Investors section of the company’s website at www.amagpharma.com.
Following the conference, the webcast will be archived on the AMAG
Pharmaceuticals, Inc. website until March 13, 2013.

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that
manufactures and markets Feraheme® (ferumoxytol) Injection for
Intravenous (IV) use in the United States. Along with driving organic
growth of its lead product, AMAG intends to expand its portfolio with
additional commercial-stage specialty pharmaceuticals. The company is
seeking complementary products that leverage the company’s commercial
footprint and focus on hematology and oncology centers and hospital
infusion centers. For additional company information, please visit www.amagpharma.com.

Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303